文献速递药物不良反应与药物警戒

机器学习预测药物不良事件的系统评价

Machine learning methods for predicting adverse drug events: A systematic review.
PubMed 文献 · Br J Clin Pharmacol · 2025-12-04

常用算法为逻辑回归、随机森林和XGBoost;67.8%研究报告AUC,其中85%内部验证AUC>0.70,但仅33.9%处理类别不平衡、18.6%进行外部验证。

要点

  • 机器学习模型对门诊ADE预测有前景,集成方法表现较好
  • 仅18.6%研究做外部验证,临床适用性受限
  • 类别不平衡处理不足,仅33.9%研究涉及

核心结论

  • 机器学习模型尤其集成方法在预测ADE方面显示潜力,但类别不平衡和外部验证不足限制其临床适用性。
  • 未来研究需采用更严格方法并基于药物警戒实践开发专用框架,以确保模型准确、可推广并整合入临床工作流。

研究设计与样本

  • 使用PROBAST工具评估偏倚风险,聚焦门诊或大规模数据源(电子健康记录、行政索赔、自发报告系统)。

主要发现

  • 逻辑回归、随机森林和XGBoost是最常用算法。
  • 67.8%研究报告AUC,其中85%内部验证AUC>0.70。
  • 仅33.9%研究处理类别不平衡,18.6%进行外部验证。
  • 方法学严谨性存在问题,尤其在缺失数据处理和验证程序方面。

临床怎么用

  • 机器学习ADE预测模型可用于识别门诊高风险患者,但需注意其外部验证不足和类别不平衡问题。
  • 临床部署前应评估模型方法学质量,优先选择经过外部验证且处理类别不平衡的模型。

局限性

  • 仅33.9%研究处理类别不平衡,18.6%进行外部验证,方法学严谨性不足。
  • 缺失数据处理和验证程序存在问题,影响模型可靠性和推广性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Predicting adverse drug events (ADEs) in outpatient settings is crucial for improving medication safety, identifying high-risk patients and reducing health-care costs. While traditional methods struggle with the complexity of health-care data, machine learning (ML) models offer improved prediction capabilities; however, their effectiveness in ADE prediction remains unclear. This systematic review evaluated ML algorithms used for this purpose, analysing studies that focussed on outpatient care or utilized large-scale data sources (e.g. electronic health records, administrative claims and spontaneous reporting systems) that primarily represent the outpatient continuum. We systematically searched MEDLINE and Embase up to December 2024 to identify studies developing or validating ML models for ADE prediction. Study characteristics, ML methods, ADE types, model performance and risk of bias were assessed using the PROBAST tool. From 59 included studies comprising 191 ML implementations, Logistic regression, Random forest and XGBoost emerged as the most commonly used algorithms. The majority of studies (67.8%) reported area under the curve (AUC), with 85% demonstrating moderate to high performance (AUC > 0.70) for internal validation. However, only 33.9% of studies addressed class imbalance, and merely 18.6% conducted external validation, raising concerns about methodological rigour, particularly in missing data handling and validation procedures. Our findings indicate that ML models, especially ensemble methods, show promise in predicting ADEs, although challenges with class imbalance and limited external validation currently hinder their clinical applicability. Future research should focus on adopting more rigorous methodologies and developing specialized frameworks for ML-based ADE prediction that build upon established pharmacovigilance practices to ensure models are accurate, generalizable, and seamlessly integrated into clinical workflows for ongoing monitoring and improved medication safety.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Chalabianloo N, Ahmadi F, Omrani MA, et al. Machine learning methods for predicting adverse drug events: A systematic review. Br J Clin Pharmacol. 2025. PMID: 41346001. doi:10.1002/bcp.70377

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。